Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about HROW, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Fluorometholone Acetate FDA approved Feb 1986 · Flarex |
Ocular Inflammation | Phase 4 · NCT07588074 | Completed |
| Cyclosporine 0.1% Ophthalmic Solution | Dry Eye Disease (DED) | N/A · NCT07904728 | Recruiting |
| Chloroprocaine Hydrochloride Ophthalmic Gel | Antiseptic | Phase 4 · NCT05934253 | Completed |
| Chloroprocaine ophthalmic gel 3% | Diabetic Macular Edema (DME) | Phase 4 · NCT07456826 | Enrolling by invitation |
| Cyclosporine emulsion | Dry Eye Disease (DED) | Phase 4 · NCT07368595 | Not yet recruiting |
| Lidocaine pledget | Macular Degeneration | Phase 4 · NCT07779356 | Completed |
| Proparacaine Hydrochloride Ophthalmic Solution… | Diabetic Macular Edema (DME) | Phase 4 · NCT07456826 | Enrolling by invitation |
| Cyclosporine Ophthalmic | Meibomian Gland Dysfunction (MGD) | Phase 4 · NCT07224529 | Recruiting |
| Triamcinolone Acetonide | Postoperative Ocular Inflammation | Phase 3 · NCT07832552 | Enrolling by invitation |
Also used in these trials (approved or third-party drugs, not HROW's own candidates): Ergocalciferol, Lidocaine Hydrochloride, Loteprednol Etabonate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
HROW holds $75.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.2M/quarter from operations, an estimated runway of 24.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HROW files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Mark L Baum CHIEF EXECUTIVE OFFICER, Director · +889,500 options |
Insider | 2,996,130 | 7.98% | 2026-05-14 |
| Daniel Kaufman | 5%+ holder (13G) | 2,898,254 | 7.72% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 2,757,783 | 7.35% | 2026-09-30 |
| Opaleye Management Inc. 10% owner |
Insider | 2,105,000 | 5.61% | 2026-09-30 |
| Andrew R. Boll PRESIDENT AND CFO · +405,750 options |
Insider | 814,679 | 2.17% | 2026-05-14 |
| John P. Saharek CEO & President, ImprimisRx |
Insider | 467,388 | 1.25% | 2025-04-03 |
| Lauren P Silvernail Director · +5,248 options |
Insider | 1,000 | 0.00% | 2026-05-18 |
| Adrienne L Graves Director · +5,248 options |
Insider | 1,000 | 0.00% | 2026-05-18 |
Share count 37,533,160 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HROW and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →